2023版子宫内膜癌FIGO分期更新对病理诊断内容的影响  

The Impact of the 2023 FIGO Staging Update of Endometrial Carcinoma on the Content of Pathological Diagnosis

作　　者：司婧文 于秀杰[1] 申彦[1] SI Jing-wen;YU Xiu-jie;SHEN Yan(Department of Pathology,Tianjin Central Hospital of Gynecology Obstetrics/Nankai University Maternity Hospital,Tianjin 300100,China)

机构地区：[1]天津市中心妇产科医院/南开大学附属妇产医院病理科,300100

出　　处：《国际妇产科学杂志》2024年第3期241-246,共6页Journal of International Obstetrics and Gynecology

基　　金：国家临床重点专科专病队列项目(GJZDZKZBDL2022-01)。

摘　　要：子宫内膜癌是女性生殖系统最常见的恶性肿瘤,近年来子宫内膜癌诊疗中备受关注的热点问题,如淋巴脉管间隙浸润的定量评价、前哨淋巴结超分期和子宫内膜癌分子分型等,已经逐渐用于临床实践。目前,子宫内膜癌相关的新进展已被写入2023版国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)子宫内膜癌分期修订版本,并在临床推广应用。规范的病理诊断是评估子宫内膜癌患者预后和指导辅助治疗的重要依据,介绍2023版FIGO子宫内膜癌分期更新对病理诊断内容的影响,旨在帮助提高病理医生子宫内膜癌病理诊断的规范化及标准化水平,辅助临床医生更准确地理解和应用新分期。Endometrial carcinoma is the most common malignancy of the female reproductive system.Recent years have witnessed pivotal developments in the diagnosis and treatment,including the quantitative assessment of lymphovascular space invasion,the ultrastaging of sentinel lymph nodes,and the molecular stratification of endometrial carcinoma,all progressively integrated into clinical practice.These new insights have been incorporated into the 2023 version of the staging system by the International Federation of Gynecology and Obstetrics(FIGO),heralding a new era of clinical adoption.The importance of precise pathological evaluation cannot be overstated,serving as a linchpin for prognosticating patient outcomes and steering the course of adjuvant therapies.Through the lens of the updated 2023 FIGO staging for endometrial carcinoma,this discourse aims to elevate the paradigm of pathological diagnosis,promoting a benchmark of standardization and precision for pathologists,thereby empowering clinicians with a deeper and more accurate application of the staging system.

关 键 词：子宫内膜肿瘤 肿瘤浸润 淋巴转移 前哨淋巴结 分子分类 国际妇产科联盟 

分 类 号：R737.33[医药卫生—肿瘤]